about
An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells.Curcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cells.Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell.Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer.Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.Ki67 is a promising molecular target in the diagnosis of cancer (review).Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.Cleavage and phosphorylation: important post-translational modifications of galectin-3.Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate.Human DBR1 modulates the recycling of snRNPs to affect alternative RNA splicing and contributes to the suppression of cancer development.A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.Ki67 targeted strategies for cancer therapy.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.PTBP1 knockdown in renal cell carcinoma inhibits cell migration, invasion and angiogenesis in vitro and metastasis in vivo via the hypoxia inducible factor-1α pathway.Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer ModelsCorrigendum to "Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models"
P50
Q34991215-46889D15-28F6-4EB3-855C-67225DEE4E1FQ35281874-53BDD097-EB9D-4FD5-8459-483FC5167942Q37187773-AEB7EE75-F202-42D7-9930-8B62F6D83115Q37406885-B74C473B-1AF1-42C9-8314-BB3A7C67B80BQ37565456-AF358A36-A4D5-40F4-881C-A45A3BF0C87DQ38025708-3E96F4B0-418D-4A3B-A571-A232DA046A01Q38225830-E2049A68-14B5-4DCC-8D60-492367B3FDB6Q38266652-7000E0C1-C0DC-466E-BAD3-75957529F26EQ39188198-C5CC1EC8-2F94-4C91-96E9-FD39F06E27B2Q39220862-7DD439AC-999C-426B-9B41-D236159894DCQ39326423-3CD382D1-A309-4E57-8641-7A2D7305DAEEQ40201325-67C2B117-40AB-427D-8205-E581D8DF74D1Q45197517-5138CD06-078F-40B9-A1B4-5A93D005CC69Q45873470-151D8992-6014-4EBA-B7AD-72F1D7C4D076Q47629566-58885E43-882E-45F3-A081-FA301170CA07Q52670032-7CCC748D-2661-499F-9AAE-A76B0F81E65AQ58564259-7575E6B6-81C7-48E5-B846-FCF8AD4BC359Q64113262-7000AF41-1C9F-4647-8031-7CBCCA6B5F33
P50
description
researcher ORCID ID = 0000-0002-8788-2880
@en
wetenschapper
@nl
name
Liantao Li
@ast
Liantao Li
@en
Liantao Li
@es
Liantao Li
@nl
type
label
Liantao Li
@ast
Liantao Li
@en
Liantao Li
@es
Liantao Li
@nl
prefLabel
Liantao Li
@ast
Liantao Li
@en
Liantao Li
@es
Liantao Li
@nl
P106
P1153
55576516100
P31
P496
0000-0002-8788-2880